Difference between revisions of "Dacarbazine (DTIC)"
Jump to navigation
Jump to search
(updated content) |
|||
| Line 9: | Line 9: | ||
==Diseases for which it is used== | ==Diseases for which it is used== | ||
| + | *[[Hodgkin lymphoma, nodular lymphocyte-predominant]] | ||
*[[Hodgkin lymphoma]] | *[[Hodgkin lymphoma]] | ||
*[[Melanoma]] | *[[Melanoma]] | ||
| + | *[[Neuroendocrine tumors]] | ||
| + | *[[Sarcoma]] | ||
==Patient drug information== | ==Patient drug information== | ||
Revision as of 02:53, 21 June 2013
Also known as DIC, DTIC-Dome, Imidazole Carboxamide.
General information
Class/mechanism: Alkylator, purine analog, inhibits DNA synthesis; exact mechanism unclear. Converted to the active alkylating metabolite MTIC.[1][2]
Route: IV
Extravasation: irritant
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Diseases for which it is used
- Hodgkin lymphoma, nodular lymphocyte-predominant
- Hodgkin lymphoma
- Melanoma
- Neuroendocrine tumors
- Sarcoma
Patient drug information
- Dacarbazine (DTIC) patient drug information (Chemocare)[3]
- Dacarbazine (DTIC) patient drug information (UpToDate)[4]